This discovery paved the way for EGFR-targeted therapies, with epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) becoming the standard first-line treatment for NSCLC [3,4,5]. Here, EGFR is linked to non-small cell lung carcinoma.